We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mutation That Induces High Blood Pressure in Women Linked to Increased Heart Attack Risk

By LabMedica International staff writers
Posted on 05 Aug 2014
A mutation in women in the G-protein coupled estrogen receptor 30 (GPER) gene generates a receptor with reduced activity that induces high blood pressure, the single biggest risk factor for heart attack and stroke.

The GPER gene is a member of the G-protein coupled receptor 1 family and encodes an integral membrane protein with high affinity for estrogen that localizes to the endoplasmic reticulum. The protein binds estrogen, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen.

Investigators at the Schulich School of Medicine & Dentistry (London, ON, Canada) found that a common missense genetic variant of GPER, P16L GPER, was poorly functional when expressed in vascular smooth muscle cells. Furthermore, females—but not males—carrying this genetic variant had increased blood pressure and had a higher allelic prevalence in a highly selected population of hard-to-treat hypertensive patients.

"This is one step in understanding the effects of estrogen on heart disease, and understanding why some women are more prone to heart attack and stroke than others," said senior author Dr. Ross Feldman, professor of medicine and physiology/pharmacology at the Schulich School of Medicine & Dentistry. "Our work is a step forward in developing approaches to treating heart disease in this under-appreciated group of patients."

The study was published in the July 21, 2014, online edition of the British Journal of Clinical Pharmacology.

Related Links:

Schulich School of Medicine & Dentistry


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Total Laboratory Automation Solution
SATLARS Mini T8

Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more